Precision diagnostics company Previse, previously known as Capsulomics, has raised USD 3 million in seed funding, with participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and angel investors. This brings total funds raised to USD 4.5 million. 

The company also launched its first laboratory-developed test, Esopredict. This test allows gastroenterologists to offer a personalized approach to treating Barrett's esophagus, a precursor to esophagus cancer. Barrett's esophagus is a condition in which the tissue lining the esophagus changes and becomes similar to the tissue that lines the intestines. This is often caused by long-term acid reflux or gastroesophageal reflux disease (GERD), and can develop into esophageal cancer. 

By analyzing a sample of a patient's Barrett's esophagus cells, Esopredict can generate a report called the Esoscore, which provides gastroenterologists with a risk prediction for the next five years. This report identifies alterations in the DNA methylation levels of four genes, allowing healthcare providers to determine a patient's likelihood of developing esophageal cancer and make informed decisions about their treatment, monitoring, and follow-up care.

The funds raised will be used to grow the business's commercial activities and to create research demonstrating the practicality of the clinical application of Esopredict, which will serve as the foundation for securing insurance coverage and reimbursement for Esopredict.

California-based Previse is a genetic testing company that specializes in developing precision medicine solutions for the early detection and treatment of different types of cancer. The company was founded in 2020 as Capsulomics, Inc. and rebranded as Previse in 2022.